Summary
The complex gating of the hERG channel makes it ideally suited to its principal role in controlling phase 3 repolarization of the cardiac ventricular action potential. Any abnormal delay in repolarization can lead to the re-activation of Ca2+ channels, giving rise to early after-depolarizations, and coupled with increased cardiac dispersion, typically associated with these delays, provides respectively both the trigger and substrate for the potentially life threatening arrhythmia Torsardes de Pointes (TdP). Owing to the fundamental role of hERG in controlling the duration of the cardiac action potential, it is not surprising that any drugs that potently and selectively block this channel are liable to have these effects. Consequently, much effort has been expended in developing standard voltage protocols to reliably assess the effects of compounds on hERG currents in vitro. This chapter describes how to record hERG currents in a recom-binant cell line using the whole-cell patch-clamp technique. It also provides typical voltage protocols used for assessing the basic electrophysiological properties of these currents and for assessing the effects of compounds on hERG tail currents.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Haverkamp, W., Breithardt, G., Camm, A.J., Janse, M.J., Rosen, M.R., Ant-zelevitch, C., Escande, D., Franz, M., Malik, M., Moss, A., and Shah, R. (2000) The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs:clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc. Res. 47,219–233.
Gupta, A., Lawrence, A.T., Krishnan, K., Kavinsky, C.J., and Trohman, R.G. (2007)Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am. Heart J. 153, 891–899.
Fermini, B. and Fossa, A.A. (2003) The impact of drug-induced QT interval prolongation on drug discovery and development. Nat. Rev. Drug Discov. 2, 439–447.
Shah, R.R. (2002) The significance of QT interval in drug development. Br. J. Clin.Pharmacol. 54, 188–202.
Dorn, A., Hermann, F., Ebneth, A., Both-mann, H., Trube, G., Christensen, K., and Apfel, C. (2005) Evaluation of a high-throughput fluorescence assay method for HERG potassium channel inhibition.J. Biomol. Screen. 10, 339–347.
Guthrie, H., Livingston, F.S., Gubler, U., and Garippa, R. (2005) A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the ion works HTTM system. J. Biomol. Screen. 10, 832–840.
Diaz, G.J., Daniell, K., Leitza, S.T., Martin, R.L., Su, Z., McDermott, J.S., Cox, B.F., and Gintant, G.A. (2004) The [3H]dofe-tilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia:comparison of intact cell and membranepreparations and effects of altering [K+]o.J. Pharmacol. Toxicol. Methods 50, 187–199.
Tang, W., Kang, J., Wu, X., Rampe, D., Wang, L., Shen, H., Li, Z., Dunnington, D., and Garyantes, T. (2001) Development and evaluation of high throughput functional assay methods for HERG potassium channel. J. Biomol. Screen. 6, 325–331.
Kamiya, K., Niwa, R., Mitcheson, J.S., and Sanguinetti, M.C. (2006) Molecular determinants of HERG channel block. Mol.Pharmacol. 69, 1709–1716.
Rodriguez-Menchaca, A., Ferrer-Villada, T., Lara, J., Fernandez, D., Navarro-Polanco, R.A. and Sanchez-Chapula, J.A. (2006) Block of HERG channels by berberine:mechanisms of voltage- and state-dependence probed with site-directed mutant channels. J. Cardiovasc. Pharmacol. 47, 21–29.
Bottino, D., Penland, R.C., Stamps, A., Traebert, M., Dumotier, B., Georgiva, A., Helmlinger, G., and Lett, G.S. (2006) Pre-clinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.Prog. Biophys. Mol. Biol. 90, 414–443.
Crumb, W.J., Jr., Ekins, S., Sarazan, R.D., Wikel, J.H., Wrighton, S.A., Carlson, C., and Beasley, C.M., Jr. (2006) Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis. Pharmacol. Res. 23, 1133–1143.
Jamieson, C., Moir, E.M., Rankovic, Z., and Wishart, G. (2006) Medicinal chemistry of hERG optimizations: highlights and hang-ups. J. Med. Chem. 49, 5029–5046.
Wible, B.A., Hawryluk, P., Ficker, E., Kury-shev, Y.A., Kirsch, G., and Brown, A.M.(2005) HERG-Lite: a novel comprehensive high-throughput screen for drug-inducedhERG risk. J. Pharmacol. Toxicol. Methods 52, 136–145.
van der Heyden, M.A., Smits, M.E., and Vos, M.A. (2007) Drugs and trafficking of ion channels: a new pro-arrhythmic threat on the horizon? Br. J. Pharmacol. 153, 406–409.
Hancox, J.C. and Curtis, M.J. (2006) Methods for screening drugs for their pro-arrhythmic liability: does the rabbit ventricular wedge hold the key? J. Pharmacol.Toxicol. Methods 54, 257–260.
Lawrence, C.L., Pollard, C.E., Hammond, T.G., and Valentin, J.P. (2005) Nonclinical proarrhythmia models: predicting Torsades de Pointes. J. Pharmacol. Toxicol. Methods 52, 46–59.
Shah, R.R. and Hondeghem, L.M. (2005)Refining detection of drug-induced proar-rhythmia: QT interval and TRIaD. Heart Rhythm 2, 758–772.
Valentin, J.P., Hoffmann, P., De Clerck, F., Hammond, T.G., and Hondeghem, L.(2004) Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. J. Pharmacol. Toxicol. Methods 49, 171–181.
Witchel, H.J., Milnes, J.T., Mitcheson, J.S., and Hancox, J.C. (2002) Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes. J. Pharmacol.Toxicol. Methods 48, 65–80.
Rudy, B. and Iversen, L.E. (eds.) (1992) Ion channels methods in enzymology 207. Academic, London.
Molleman, A. (2003) Patch clamping: an introductory guide to patch clamp electro-physiology. Wiley, Chichester.
Sakmann, B. and Neher E. (eds.) (1995) Single-channel recording. Plenum, New York.
Yao, J.A., Du, X., Lu, D., Baker, R.L., Daharsh, E., and Atterson, P. (2005) Estimation of potency of HERG channel blockers: impact of voltage protocol and temperature. J. Pharmacol. Toxicol. Methods 52, 146–153.
Rampe, D., Roy, M.L., Dennis, A., and Brown, A.M. (1997) A mechanism for the proarrhythmic effects of cisapride (Propul-sid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett. 417, 28–32.
Acknowledgments
I would like to thank the Millipore Ion Channel Group (Cambridge, UK) particularly Helen Swain and Louise Webdale for help with the tissue culture and cell preparation sections.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Helliwell, R.M. (2008). Recording hERG Potassium Currents and Assessing the Effects of Compounds Using the Whole-Cell Patch-Clamp Technique. In: Lippiat, J.D. (eds) Potassium Channels. Methods in Molecular Biology, vol 491. Humana Press. https://doi.org/10.1007/978-1-59745-526-8_22
Download citation
DOI: https://doi.org/10.1007/978-1-59745-526-8_22
Publisher Name: Humana Press
Print ISBN: 978-1-934115-65-7
Online ISBN: 978-1-59745-526-8
eBook Packages: Springer Protocols